Overview
Compare with American Picture House Corp, Nomadar Corp. or SafeSpace Global Corp, or pick any stock.
- TickerACBM on OTC1
- IndustryServices-Amusement & Recreation Services1
- HeadquartersFishers, Indiana1
- Incorporated inNV2
- Business address12175 Visionary Way, Suite 1160, Fishers, In 460382
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Since January 30, 2017, following a change of control, our business has been the development and marketing nutritional products that promote wellness and a healthy lifestyle. Our revenue to date has resulted from the purchase of products from three suppliers in the Republic of China (Taiwan), one of which accounted for all of our purchases in the year ended December 31, 2022. We have not generated any revenue in the second and third quarters of 2022 and subsequent to December 31, 2022 through the date of this annual report, and we did not purchase any inventory since the second quarter of 2022.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $0 | $0 |
| Selling, general and administrative | $154.0K | $38.0K |
| Total operating expenses | $154.0K | $38.0K |
| Loss from operations | -$154.0K | -$38.0K |
| Liability forgiveness | $62.0K | $0 |
| Interest expense - related parties | -$9.2K | -$4.3K |
| Total other expenses | $52.9K | -$4.3K |
| Loss before income tax expense | -$101.1K | -$42.3K |
| Income tax expense | $0 | $0 |
| Net loss | -$101.1K | -$42.3K |
| Basic and diluted loss per share of common stock | $0.00 | $0.00 |
| Weighted average number of shares of common stock outstanding | 60.0M shares | 60.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $4.1K | $476 | $376 |
| Prepaid Expense | $10.0K | $0 | |
| Security deposit | $0 | $4.6K | |
| Total Current Assets | $14.1K | $5.1K | |
| Operating lease right of use asset | $0 | $26.9K | |
| TOTAL ASSETS | $14.1K | $32.0K | |
| Accounts payable and accrued expenses | $55.5K | $154.5K | |
| Deferred revenue | $20.0K | $20.0K | |
| Due to related parties | $325.5K | $125.6K | |
| Operating lease liabilities - current | $0 | $26.9K | |
| Total Current and Total Liabilities | $401.1K | $326.9K | |
| Preferred stock: 25,000,000 authorized; $0.001 par value; no shares issued and outstanding | $0 | $0 | |
| Common stock: 100,000,000 authorized; $0.001 par value; 60,042,000 shares issued and outstanding | $60.0K | $60.0K | |
| Additional paid-in capital | $32.3M | $32.3M | |
| Accumulated deficit | -$32.8M | -$32.7M | |
| Total Stockholders' Deficit | -$387.0K | -$295.0K | -$257.0K |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $14.1K | $32.0K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 25.0M shares | 25.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 60.0M shares | 60.0M shares | |
| Common stock, shares outstanding | 60.0M shares | 60.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $4.1K | $476 | $376 |
| Prepaid Expense | $10.0K | $0 | |
| Security deposit | $0 | $4.6K | |
| Total Current Assets | $14.1K | $5.1K | |
| Operating lease right of use asset | $0 | $26.9K | |
| TOTAL ASSETS | $14.1K | $32.0K | |
| Accounts payable and accrued expenses | $55.5K | $154.5K | |
| Deferred revenue | $20.0K | $20.0K | |
| Due to related parties | $325.5K | $125.6K | |
| Operating lease liabilities - current | $0 | $26.9K | |
| Total Current and Total Liabilities | $401.1K | $326.9K | |
| Preferred stock: 25,000,000 authorized; $0.001 par value; no shares issued and outstanding | $0 | $0 | |
| Common stock: 100,000,000 authorized; $0.001 par value; 60,042,000 shares issued and outstanding | $60.0K | $60.0K | |
| Additional paid-in capital | $32.3M | $32.3M | |
| Accumulated deficit | -$32.8M | -$32.7M | |
| Total Stockholders' Deficit | -$387.0K | -$295.0K | -$257.0K |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $14.1K | $32.0K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 25.0M shares | 25.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 60.0M shares | 60.0M shares | |
| Common stock, shares outstanding | 60.0M shares | 60.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$101.1K | -$42.3K |
| Imputed interest - related parties | $9.2K | $4.3K |
| Liability forgiveness | -$62.0K | $0 |
| Security deposit | $4.6K | $0 |
| Prepaid expenses | -$10.0K | $1.2K |
| Accounts payable and accrued expenses | -$36.9K | $16 |
| Net cash used in operating activities | -$196.3K | -$36.7K |
| Advances from related parties | $199.9K | $36.8K |
| Net cash provided by financing activities | $199.9K | $36.8K |
| Net change in cash | $3.6K | $100 |
| Cash paid for income taxes | $0 | $0 |
| Cash paid for interest | $0 | $0 |
No quarter-by-quarter statement was filed.
What it owns
What ACRO BIOMEDICAL CO., LTD. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Operating-lease assets (leased space) | $09 Dec 31, 2025 | $26.9K9 Dec 31, 2024 | −100.0% |
Properties, in its own words
On November 1, 2023, we entered into a lease agreement to rent a storage facility in Hong Kong for a two-year term at an annual rental of HK$17,900 (approximately $2,315) per month and with a HK$35,800 (approximately $4,600) as a security deposit. On August 30, 2025, the Company terminated the lease agreement.
Item 2 of the 10-K filed Feb 11, 2026.3
Leadership
Who has led ACRO BIOMEDICAL CO., LTD., and when. Pick a name to see everywhere that person has worked.
Chief executive
- Chief executive officerPao-Chi Chu Feb 26, 2021 to Feb 26, 202112
Board members and other officers (1)
- Board memberPao-Chi Chu Feb 26, 2021 to Feb 26, 202112
Former names
- KILLER WAVES HAWAII, INCOct 23, 2014 to Jan 30, 20172
Timeline
Filings
29 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 4 major events, 5 other. The latest 20:
- Sep 2, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- May 5, 202610-Q EDGAR
- Feb 11, 202610-K EDGAR
- Jan 8, 20268-K EDGAR
- Nov 10, 202510-Q EDGAR
- Aug 14, 20258-K EDGAR
- Aug 5, 202510-Q EDGAR
- Jul 24, 202510-Q EDGAR
- Jul 24, 202510-K EDGAR
- Jul 23, 202510-Q EDGAR
- Jul 23, 202510-Q EDGAR
- Jul 22, 202510-Q EDGAR
- Jul 18, 202510-K EDGAR
- Jul 11, 202510-Q EDGAR
- Jul 2, 20258-K EDGAR
- Nov 15, 2023NT 10-Q FORM 12B-25 EDGAR
- Aug 14, 202310-Q FROM 10-Q EDGAR
- Aug 2, 202310-Q EDGAR
- Jul 21, 202310-K EDGAR
The 29 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How ACRO BIOMEDICAL CO., LTD. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARACRO BIOMEDICAL CO., LTD.1
- CIK0001622996
- Employer ID (EIN)47-19503563
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
- Incorporated inNevada3
- Fiscal year endsDecember 311
- Industry code (SIC)7900 Services-Amusement & Recreation Services1
- SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
- Business address12175 Visionary Way, Suite 1160, Fishers, IN 460381
- Phone(317) 286-67881
- Shares outstanding60,042,000 as of Aug 5, 202611
- Public float$21.0K as of Jun 30, 20253
- AuditorWeinberg & Company, P.A., Los Angeles, California PCAOB ID 572; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceOct 23, 20141
- Filings91 in all: 10-Q (31), 8-K (11), 10-K (10), NT 10-Q (10), NT 10-K (5), CORRESP (3), EFFECT (3), S-1/A (3)1
All 19 form types
UPLOAD (3), POS AM (2), S-1 (2), 10-12G (1), 10-K/A (1), 10-KT (1), 424B3 (1), 5 (1), D (1), S-8 (1), SC 13D (1)
- Latest filingsAnnual report (10-K) Feb 11, 2026
Quarterly report (10-Q) Aug 14, 2026
Latest 8-K (8-K) Sep 2, 2026
Risk factors and legal proceedings
The risks ACRO BIOMEDICAL CO., LTD. names in Item 1A of its 10-K filed Feb 11, 2026: 32 risks under these headings, as written.3
- We have not generated any revenues subsequent to December 31, 2022 through the date of this annual report, we are operating at a loss, and we cannot assure you that we can or will ever generate revenue or operate profitably.
- We require significant funding for us to conduct our business.
- Our financial statements include a going concern paragraph.
- If we are not able to generate revenue and develop a customer base, we may not be able to operate profitably.
- Our revenue has been impaired by Chinese government’s efforts to politically stabilize Hong Kong and the effects of China’s COVID-19 restrictions.
- Outbreaks of communicable diseases, natural disasters or other events have materially and adversely affected, and in the future, may materially and adversely affect our business, results of operations and financial condition.
- If we sell products or commence operations in the United States, we would be subject to government regulations in the United States.
- If we sell our products to customers in Taiwan and Hong Kong, which was customer base, we may be subject Taiwan and Hong Kong laws and regulations relating to our products.
- If we develop a chicken feed product, which would be used by chicken farmers to feed their chicken, we may be subject to government regulations.
- We need to develop additional sources of supply.
- We need to develop and maintain marketing and distribution channels.
- We do not have product liability insurance to protect us against any claims we may sustain.
The other 20 risks
- The market for our products is very competitive, and we may not be able to compete successfully.
- We have not conducted any study of the potential market for cordyceps-based in the United States and we cannot assure you that there is a significant market for these products in the United States.
- The market for cordyceps products, including any chicken feed product we may develop may be affected by recalls or successful litigation arising from claimed adverse reactions to products.
- The market for our products may be dependent on public tastes, which can rapidly change.
- We may not be successful in any research and development activities in which we may engage.
- We are dependent upon our chief executive officer.
- If we are unable to attract, train and retain technical and financial personnel, our business may be materially and adversely affected.
- We may not be able to protect any intellectual property which we may develop.
- Our business and our ability to generate a sufficient gross margin to enable us to operate profitably may be affected by inflation, the global supply chain issues and the aftereffects of China’s COVID-19 restrictions..
- Risks Concerning our Common Stock
- There is presently no active market for our common stock, which is currently on the OTC Expert Market, which may make it difficult for you to buy or sell your stock.
- If a market for our common stock develops after we are no longer on the Expert Market, because our common stock would be a penny stock, you may have difficulty selling our common stock in the secondary trading market.
- Our lack of internal controls over financial reporting may affect the market for and price of our common stock.
- Our lack of a full-time chief financial officer affects our ability to develop financial controls, which could affect the market price for our common stock.
- We do not have any independent directors.
- Our failure to have filed timely reports with the SEC in a timely manner may impair the market for and the value of our common stock.
- Because our sole director is located outside of the United States, investors may not be able to enforce federal securities laws or their other legal rights against him.
- Our stock price may be volatile and your investment in our common stock could suffer a decline in value.
- Raising funds by issuing equity or convertible debt securities could dilute the net tangible book value of the common stock and impose restrictions on our working capital.
- Because of our former chief executive officer’s stock ownership, he has the power to elect all directors and to approve any action requiring stockholder approval.
- We do not intend to pay any cash dividends in the foreseeable future.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARPao-Chi Chu, Chief executive officer
- 13SEC EDGARExecutive or director change
- 14SEC EDGARChange of auditor
- 15SEC EDGARExecutive or director change
- 16SEC EDGARChange of auditor